ArticlePharmaceutics2022
Isolation and Molecular Characterization of a Novel Lytic Bacteriophage That Inactivates MDR
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Phage anti-defense genes targeting NADVirulence · 2026Article
- Unraveling a new Klebsiella phage KP47 against Klebsiella spp.BMC microbiology · 2026Article
- Isolation and characterization of novel bacteriophages with broad-spectrum lytic activity against carbapenem-resistant Klebsiella pneumoniae capsular pathotypes K1, K2, K3, K5, and K20.Biology direct · 2026Article
- Phage-antibiotic combination: a possible approach to combatting multidrug-resistant Klebsiella pneumoniae.AMB Express · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Characterization and Therapeutic Potential of a Novel Lytic Bacteriophage vB_Kp_H122 Targeting Multidrug-Resistant Hypervirulent Klebsiella pneumoniae of K57 Capsular Type.Transboundary and emerging diseases · 2026Article
- Three Novel Bacteriophages for the Biocontrol ofPathogens (Basel, Switzerland) · 2025Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- Newly isolated bacteriophages show efficacy and phage-antibiotic synergy in vitro against the equine genital pathogens Klebsiella pneumoniae and Pseudomonas aeruginosa.BMC veterinary research · 2025Article
- Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.AMB Express · 2025Article
- A NewPharmaceutics · 2024Article
- Analysis of a new phage, KZag1, infecting biofilm of Klebsiella pneumoniae: genome sequence and characterization.BMC microbiology · 2024Article
- Potential of an Isolated Bacteriophage to InactivateAntibiotics (Basel, Switzerland) · 2024Article
- Article
- High activity and specificity of bacteriophage cocktails against carbapenem-resistantFrontiers in microbiology · 2024Article
- Newly Isolated Virulent Salmophages for Biocontrol of Multidrug-ResistantInternational journal of molecular sciences · 2023Article
- New Bacteriophages Members of thePHAGE (New Rochelle, N.Y.) · 2023Article
- An Edible Biopolymeric Microcapsular Wrapping Integrating Lytic Bacteriophage Particles forAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
The worldwide increase in serious infections caused by multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.